A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the Second-Line treatment of metastatic KRAS mutant colorectal adenocarcinoma

J. Randolph Hecht, Al B. Benson, Dmitry Vyushkov, Yingsi Yang, Johanna Bendell, Udit Verma

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Fingerprint

Dive into the research topics of 'A phase II, randomized, double-blind, placebo-controlled study of simtuzumab in combination with FOLFIRI for the Second-Line treatment of metastatic KRAS mutant colorectal adenocarcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences